MedTrace Logo

PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort

NCT07560215 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-05-01

No results posted yet for this study

Summary

PROMET-BR is an observational, retrospective and prospective real-world study in Brazil designed to characterize clinically relevant molecular alterations in metastatic prostate cancer and explore their association with patient outcomes in routine practice. The study will be conducted within Oncoclínicas \& Co and will integrate centralized biomarker testing performed at OC Precision Medicine laboratories with retrospectively assembled clinical data from electronic health records (EHRs) from participating sites. Treatments are not assigned by the protocol; patients receive standard-of-care palliative systemic therapy at the discretion of their treating physicians.

Conditions

Interventions

DIAGNOSTIC_TEST

Archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.

The exposure/intervention under investigation is the use of archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07560215 on ClinicalTrials.gov